[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-b-cell-marginal-zone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-b-cell-marginal-zone":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100600733","phase-1-a-study-of-ly4152199-in-participants-with-previously-treated-b-cell-malignancies-baffrontier-1--100600733",false,"NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )","BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies","BAF_FRontier-1","Inclusion Criteria:\n\n* Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma.\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator.\n* Participants with select tumor types must have measurable or assessable disease as defined below:\n\n  * Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement.\n  * Participants with Waldenstrom macroglobulinemia (WM) must have measurable disease, defined as the presence of serum IgM with a minimum IgM level of greater than (\\>)2 times (×) upper limit of normal (ULN) based on local laboratory testing.\n* Must be able to comply with inpatient\u002Foutpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation.\n* Must have adequate organ function.\n\nPhase 1 Dose Escalation (Cohort A) Participants - Must have histologically confirmed relapsed\u002Frefractory B-cell malignancy.\n\nPhase 1 Dose Optimization (Cohort B) Participants\n\n\\- Must have histologically confirmed relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL) de novo or transformed from follicular lymphoma (FL).\n\nExclusion Criteria:\n\nAll Participants\n\n* Known or suspected peripheral blood involvement by malignant cells with an absolute lymphocyte count of greater than or equal to (≥) 5000 cells per microliter (μL).\n* Known or suspected central nervous system (CNS) involvement by systemic lymphoma.\n* Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 at the time of starting trial treatment except for alopecia.\n* Autologous stem cell transplantation within 100 days of this study for post autologous transplant individuals.\n* Residual symptoms of neurotoxicity or cytopenias from prior chimeric antigen receptor T-cell therapy (CAR-T) or bispecifics. Exception: Cytopenia related to prior CAR-T or bispecifics allowed if they meet the adequate organ function criteria.\n* Known or suspected history of macrophage activation syndrome or hemophagocytic lymphohistiocytosis (HLH).\n* Active second malignancies, unless in remission, with life expectancy greater than 2 years with Sponsor approval.\n* History of autoimmune disease\n* Significant cardiovascular disease\n* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process\n* Vaccination with a live vaccine within 4 weeks prior to signing informed consent form (ICF).\n* Have current or had a history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins).\n* Prior treatment with B-cell activating factor receptor (BAFF-R) directed therapies (e.g., monoclonal antibody, CAR-T or bispecific antibody).\n* Pregnant and\u002For planning to breastfeed during the trial or within 90 days of the last dose of study intervention.\n* Known hypersensitivity to any component or excipient of LY4152199.","ALL","18 Years",{"count":20,"type":21},215,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.",[27,28,29,30,31,32,33],"Lymphoma, Non-Hodgkin","B-cell Lymphoma","Lymphoma, Large B-Cell, Diffuse","Lymphoma, Follicular","Lymphoma, B-cell Marginal Zone","Waldenstrom Macroglobulinemia","Lymphoma, Mantle Cell",[35,36],"B- cell activating factor receptor (BAFFR)","Bispecific antibody","NOT_YET_RECRUITING","2026-06-19",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2029-09",{"name":47,"class":48},"Eli Lilly and Company","INDUSTRY",50,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100629569","a-study-to-evaluate-mtm-h-001-injection-in-adult-participants-with-relapsed-or-refractory-b-cell-malignancies-100629569","NCT07476378","A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies","An Open-label, Single-arm, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Efficacy of MTM-H-001 in the Treatment of Adult Participants With Relapsed or Refractory B-cell Malignancies (Archonc-001)","Archonc-001","Inclusion Criteria:\n\n1. Male or female, aged 18 - 75 years old (inclusive);\n2. The participant or his\u002Fher legally acceptable representative gives consent to this clinical study participation and signs an Informed Consent Form (ICF) indicating their understanding of the objectives and procedures of the clinical study and willingness to participate in the study;\n3. Participants with histopathologically and immunohistochemically confirmed Non-Hodgkin B-cell Lymphoma (B-NHL) according to the 2016 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues (CLL\u002FSLL diagnosed in accordance with 2018 iwCLL criteria)\n4. Relapsed or refractory disease after receiving at least two prior lines of standard therapy, or relapsed or refractory disease after receiving autologous hematopoietic stem cell transplant (ASCT) (if applicable).\n5. Adequate major organ function, defined as meeting the following criteria:\n\n   1. Hematology: Hemoglobin (Hb) ≥80 g\u002FL; absolute neutrophil count (ANC) ≥1.0×10\\^9\u002FL; and platelet count (PLT) ≥75×10\\^9\u002FL;\n   2. Coagulation: International Normalized Ratio (INR) ≤1.5×Upper Limit of Normal (ULN) and Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN;\n   3. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.0×Upper Limit of Normal (ULN);\n   4. Serum Total Bilirubin (TBIL) ≤1.5×ULN (except for participants with documented Gilbert's syndrome);\n   5. Blood creatinine (Cre) ≤1.5×ULN, or calculated creatinine clearance (Ccr) ≥50 mL\u002Fmin (using the Cockcroft-Gault formula);\n   6. Cardiac function: Good hemodynamic stability, Left Ventricular Ejection Fraction (LVEF) ≥50%;\n6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-2;\n7. Expected survival \\>3 months;\n8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and agree to use at least one effective contraceptive method throughout the study and within 6 months after the last treatment cycle.\n\nExclusion Criteria:\n\n1. B-NHL participants with a history of Richter's transformation of chronic lymphocytic leukemia (CLL).\n2. Primary central nervous system (CNS) lymphoma, or malignant tumors involving the CNS.\n3. Burkitt's lymphoma\u002Fleukemia, primary mediastinal large B-cell lymphoma (LBCL).\n4. Known history of other malignancies within the past 5 years, excluding cured localized tumors (including cervical carcinoma in situ, basal cell carcinoma of the skin, and prostate carcinoma in situ, etc.);\n5. Active hepatitis B virus (HBV) infection;\n6. Active hepatitis C virus (HCV) infection;\n7. Active human immunodeficiency virus (HIV) infection or a past history of HIV infection;\n8. Uncontrolled active infection requiring intravenous treatment within one week prior to the first dose;\n9. Corrected QT interval using Fridericia (QTcF) is ≥450 ms (male) or ≥470 ms (female) according to the electrocardiography (ECG) examination results at screening;\n10. Currently experiencing or having experienced within the past 6 months any of the following:\n\n    1. Congestive heart failure (New York Heart Association \\[NYHA\\] Class III-IV);\n    2. Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg with medication treatment;\n    3. Myocardial infarction, clinically significant arrhythmias, unstable angina, Torsades de Pointes, left bundle branch block or bifascicular block, coronary\u002Fperipheral artery bypass grafting, congenital long QT syndrome;\n    4. Cerebrovascular accident, transient ischaemic attack;\n    5. Symptomatic pulmonary embolism;\n11. History of any mental disorders (e.g., schizophrenia, bipolar disorder, eating disorders, major depression, or anxiety) as reported by the participant or documented in medical records;\n12. Pregnant or breastfeeding women.","75 Years",{"count":60,"type":21},69,[62],"NA","This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with relapsed\u002Frefractory (R\u002FR) B-cell malignancies.",[65,30,66,67,68,69],"Lymphoma, Large B-Cell, Diffuse (DLBCL)","Lymphoma, Mantle-Cell","Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)","Lymphoma, B-Cell, Marginal Zone","Transformed Follicular Lymphoma (TFL)","2026-03-12",{"date":72,"type":41},"2026-03-17",{"date":74,"type":21},"2026-03",{"date":76,"type":21},"2028-06",{"name":78,"class":79},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1]